Of note, patients with EGFR mutations and a fraction of those with activating KRAS mutant NSCLC show limited benefit from currently available ICIs, which makes these populations interesting candidates for testing the antitumor effect of the CCR2-STING iADC alone or in combination with other targeted therapies. This evidence concerns the gene STING1 and non-small cell lung carcinoma.